EW

Edwards Lifesciences
D

EW

Arincen78/100B

Edwards Lifesciences cash flow statement 1999–2026

Edwards Lifesciences's free cash flow over the last twelve months was 1.42B USD: operating cash flow of 1.72B USD less 292.80M USD of capital spending. That is 21.3% of its revenue and 2.46 a share.

Operating cash flow Free cash flow

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Net income
1.01B1.07B4.17B1.40B1.52B1.50B823.40M1.05B722.20M583.60M569.50M
Depreciation and amortization
171.20M156.60M155.20M144.90M139.60M134.80M107.20M89.30M77.40M81.90M71.20M
Stock-based compensation
172.80M158.10M162.30M139.40M126.80M109.30M92.60M81.30M71.00M61.60M56.90M
Change in working capital
-81.00M154.60M-259.30M-526.30M-421.40M145.30M42.20M-204.30M-42.60M234.20M66.10M
Change in receivables
-115.60M-23.00M121.20M-141.20M-84.10M-112.40M283.90M-94.80M-13.00M-3.90M-56.70M
Change in inventory
-38.70M50.70M-256.10M-289.00M-213.40M19.00M-120.60M-105.40M-65.70M-124.00M-65.60M
Change in payables
12.50M395.10M89.50M146.00M-21.40M195.20M-84.50M-63.50M192.50M85.20M74.00M
Change in other working capital
60.80M-268.20M-213.90M-242.10M-102.50M43.50M-36.60M59.40M-156.40M276.90M114.40M
Other non-cash items
363.50M174.10M-3.36B7.50M105.80M-119.00M38.30M154.10M126.10M21.60M-21.90M
Operating cash flow
1.72B1.60B542.30M895.80M1.22B1.73B1.05B1.18B926.80M1.00B704.40M
Operating cash flow growth
+68.85%+194.15%-39.46%-26.47%-29.67%+64.29%-10.61%+27.26%-7.38%+42.06%+28.14%
Capital expenditure
-292.80M-260.20M-252.40M-266.30M-264.80M-329.80M-407.30M-278.40M-241.70M-175.50M-217.40M
Acquisitions
—0.00-1.06B-95.20M0.00329.80M407.30M-100.20M-6.20M-184.60M-5.70M
Purchases of investments
-2.72B-3.14B-945.80M-105.50M-778.90M-1.89B-861.70M-603.10M-471.90M-1.35B-1.07B
Sales and maturities of investments
2.45B2.88B857.60M715.80M1.36B529.20M777.00M409.90M801.30M1.10B1.09B
Other investing
-139.60M-195.70M3.75B-75.00M-63.10M-359.30M-446.40M-24.00M-4.80M-43.10M1.20M
Investing cash flow
-740.70M-712.90M2.31B173.80M252.30M-1.72B-531.10M-595.80M76.70M-647.20M-211.70M
Debt issued (repaid)
—0.000.00-300.00K-200.00K-1.80M-800.00K-10.00M-437.30M176.30M222.10M
Shares issued
191.50M174.10M0.000.000.000.000.00160.50M147.00M113.80M103.30M
Share buybacks
-754.60M-893.40M-1.16B-879.60M-1.73B-512.80M-625.40M-263.30M-795.50M-763.30M-662.30M
Dividends paid
—0.000.000.000.000.000.000.000.000.000.00
Other financing
-600.00K-237.50M176.40M168.90M142.80M158.30M139.30M157.70M131.60M113.80M171.70M
Financing cash flow
-563.70M-956.80M-983.00M-711.00M-1.58B-356.30M-486.90M-115.60M-1.10B-473.20M-268.50M
Net change in cash
417.60M-119.30M1.91B375.40M-94.80M-332.80M15.80M465.00M-104.20M-111.80M211.70M
Free cash flow
1.42B1.34B289.90M629.50M953.40M1.40B647.00M901.00M685.10M825.20M487.00M
Free cash flow growth
+77.08%+360.50%-53.95%-33.97%-32.01%+116.74%-28.19%+31.51%-16.98%+69.45%+9.88%
Free cash flow margin
21.34%22.00%5.33%12.56%17.71%26.80%14.75%20.72%18.40%24.02%16.43%
Free cash flow per share
2.462.280.481.031.532.221.021.421.071.270.75
Free cash flow per share growth
+79.70%+371.12%-53.17%-32.37%-31.25%+116.98%-27.66%+32.38%-16.08%+70.94%+11.14%
Interest paid
——19.60M19.90M19.30M20.20M19.90M19.90M30.10M19.90M16.10M
Income taxes paid
—0.001.20B470.10M504.10M182.50M197.90M61.50M223.70M143.70M99.90M

Figures in USD. Free cash flow is operating cash flow less capital expenditure; owner earnings take off only the spending that keeps the business as it is, not the spending to grow it (an estimate by Financial Modeling Prep). Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Figures underlined with dots are from the company's SEC filings, where our data provider's differ.

Common questions about Edwards Lifesciences's cash flow

Source: Financial Modeling Prep